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Abstract 20 
 21 
Aims 22 
Prescribing is a complex skill required of doctors and, increasingly, other healthcare 23 
professionals. Use of a personal formulary can help to develop this skill. In 2006-9, 24 
we developed a core list of the 100 most commonly prescribed drugs. Our aim in the 25 
present study was to update this ‘starter formulary’ to ensure its continued 26 
relevance for prescriber training. 27 
Methods 28 
We analysed large contemporary primary and secondary care datasets to identify 29 
the most frequently prescribed medicinal products. Items were classified into 30 
natural groups, broadly following their British National Formulary classification. The 31 
resulting drug groups were included in the core list if they comprised ≥0.1% 32 
prescriptions in both settings or ≥0.2-0.3% prescriptions in one setting. Drugs from 33 
emergency guidelines that did not qualify by prescribing frequency completed the 34 
list. 35 
Results 36 
Over 1 billion primary care items and approximately 1.8 million secondary care 37 
prescriptions were analysed. The updated list comprises 81 drug groups commonly 38 
prescribed in both settings; 6 from primary care; 7 from secondary care; and 6 from 39 
emergency guidelines. 88% of the formulary was unchanged. Notable changes 40 
include entry of newer anti-epileptics and dipeptidyl peptidase-4 inhibitors and exit 41 
of phenytoin and thiazolidinediones. 42 
Conclusions 43 
The relative stability of the core drug list over 9 years and the current update ensure 44 
that learning based on this list remains relevant to practice. Trainee prescribers may 45 
be encouraged to use this ‘starter formulary’ to develop a sound basis of prescribing 46 
knowledge and skills that they can subsequently apply more widely. 47 
 48 
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  51 
Structured summary 52 
1: What is already known about this subject:  53 
• Prescribing is a complex skill, acquisition of which can be facilitated by use of 54 
a personal formulary 55 
• In 2006-9 we developed a ‘starter formulary’ of the 100 drugs most 56 
commonly prescribed in the UK 57 
• This drug list remained stable over 2 years and was consistent with practice 58 
of new prescribers 59 
2: What this study adds:  60 
• We used primary and secondary prescribing data from 2015 to update the 61 
‘starter formulary’ 62 
• Most drugs in the list remain the same, with 12 differences attributable to 63 
changes in practice, disease prevalence and methodology 64 
• The list is intended not to stifle trainees’ inquisitiveness, but to provide an 65 
evidence-based starting point from which they can build their prescribing 66 
knowledge and skills 67 
 68 
 69 
 70 
  71 
Introduction 72 
In Outcomes for Graduates, the General Medical Council emphasises the safe, 73 
effective and economical prescription of drugs as a core skill for all new UK medical 74 
graduates [1]. The importance of prescribing skills is further emphasised by the UK 75 
Prescribing Safety Assessment, which all new doctors must pass as a requirement of 76 
the Foundation Programme [2,3]. Prescribing is a complex, multi-step process that 77 
includes defining the clinical problem and therapeutic objectives; identifying a 78 
suitable treatment; starting the treatment; giving appropriate information; and 79 
monitoring treatment success [4]. The challenge faced by trainee prescribers in 80 
acquiring this skill is compounded by the large number of drugs available. For 81 
example, in the UK, 1,603 drugs and 18,408 preparations are licensed for 82 
prescription [personal communication, British National Formulary (BNF) editorial 83 
team, October 2017]. 84 
To facilitate development and maintenance of prescribing competence, the World 85 
Health Organisation (WHO) recommends that prescribers develop a list of ‘P’ drugs – 86 
a personal formulary of drugs that they prescribe regularly and can become familiar 87 
with [4]. This is difficult for undergraduate medical students who are not yet 88 
prescribing and who may see diverse practice as they rotate through healthcare 89 
settings and specialties. De Vries and colleagues found that provision of any 90 
formulary, whether learner or teacher-led, helped students to improve their 91 
prescribing skills [5]. In 2011, we therefore developed a ‘starter formulary’ of the 92 
100 drugs most commonly prescribed in the UK from analysis of primary and 93 
secondary care prescribing data [6]. This helped students to focus their initial 94 
learning on drugs they would actually prescribe in practice and supported educators 95 
in developing learning resources and assessments [7]. 96 
Our original list was developed from analysis of primary and secondary care 97 
prescribing data from 2006-9. Over the last 5-10 years, there have been significant 98 
therapeutic advances, including the advent of direct oral anticoagulants and 99 
dipeptidyl peptidase 4 inhibitors. The aim of this study was to update the starter 100 
formulary by identifying the drugs most commonly prescribed in primary and 101 
secondary care in 2015, thereby supporting relevant modern-day learning for new 102 
prescribers. 103 
  104 
Methods 105 
Overview 106 
NHS Prescription Cost Analysis (PCA) data was used to identify all items dispensed in 107 
the community in England in 2015 [8]. Electronic prescription records were used to 108 
identify all items prescribed in the University Hospital Birmingham NHS Foundation 109 
Trust in 2015. Medicinal products identified in each healthcare setting were formed 110 
into natural groups, guided by their classification in the British National Formulary 111 
(BNF) [9]. The most commonly prescribed drug groups in both or either setting were 112 
combined with drugs identified from emergency guidelines to generate the final core 113 
drug list. 114 
Study approvals 115 
This study did not require ethical approval as it was based wholly on aggregate data, 116 
with no linkage to patient-level data  117 
Data collection 118 
Primary care 119 
NHS PCA data for England 2015 was obtained. This is based on information obtained 120 
from prescriptions sent to the Prescription Pricing Division of the NHS Business 121 
Services Authority. All prescriptions dispensed in the community are included, the 122 
majority of which are written by general practitioners. Analysis was based on the 123 
frequency with which each medicinal product was dispensed. 124 
Secondary care 125 
A list of all items prescribed in University Hospital Birmingham NHS Foundation Trust 126 
in 2015 was obtained from their electronic prescribing system. Analysis was based 127 
on the frequency of medicinal product prescription. 128 
Emergency drugs  129 
A review of hospital guidelines generated a list of all emergency drugs used in 130 
hospital emergency settings [10]. 131 
Compiling the core list 132 
In accordance with a prospectively defined analysis plan, the PCA dataset was 133 
cleaned to remove items that fell outside the definition of a medicinal product [11] 134 
(e.g. sunscreens, camouflages, appliances and nutritional supplements). We also 135 
removed intravenous fluid preparations and vaccines because, although they fall 136 
within the definition of medicinal products, we judged that they represent 137 
educationally distinct groups. Finally, we planned to apply clinical–educational 138 
judgment to remove drugs used in highly specialised practice that fell outside the 139 
scope of a core drug list for trainee prescribers. 140 
The PCA data was used to develop natural drug groups. Medicinal products were 141 
first classified by BNF sub-paragraph. The products within each sub-paragraph were 142 
then classified by chemical name to identify and separate individual drug classes. 143 
Where several chemical entities fell naturally into a drug class, this was used as a 144 
group for analysis purposes. Conversely, where a chemical entity fell into a class of 145 
its own, it was named and analysed as such. For example, the BNF sub-paragraph 146 
‘Lipid-regulating drugs’ was separated into statins, fibrates and ezetimibe. In a few 147 
cases, e.g. ‘Nicotine replacement and related drugs’, the BNF sub-paragraph was 148 
retained as the basis for the drug group. Where necessary, clinical judgment was 149 
applied to ensure groupings were natural and clinically applicable. The drug groups 150 
developed from the PCA data were then used to sort drugs in the secondary care 151 
data. 152 
Compound products were not included as distinct items if their constituent 153 
ingredients were already captured in the top 100 list. Where different members of 154 
drug classes were used for more than one indication the drug class was included only 155 
once (e.g. H1 receptor antagonists for nausea, allergy) and the frequencies summed.  156 
Prescribing frequency 157 
For the PCA data, the number of items dispensed for all medicinal products within 158 
each drug group was summed and expressed as a percentage of the total number of 159 
items dispensed. 160 
For the secondary care data, the number of prescriptions written for all medicinal 161 
products within each drug group was summed and expressed as a percentage of the 162 
total number of prescriptions. 163 
Generating the top 100 drug list 164 
Prior to the analysis it was decided that the list would contain 100 drug groups as a 165 
number that was educationally attractive, sufficient to cover most prescribing by 166 
foundation doctors [6] and limited enough to be considered core. 167 
Drug groups qualified for the top 100 list if they comprised ≥0.1% prescriptions in 168 
both primary and secondary care; ≥0.2% prescriptions in primary care but <0.1% 169 
prescriptions in secondary care; or ≥0.3% prescriptions in secondary care but <0.1% 170 
prescriptions in primary care. These definitions were chosen to optimise inclusion of 171 
drugs that were widely prescribed across healthcare systems and to reduce the 172 
inclusion of more specialist drugs e.g. those with high use by a single specialist team 173 
in secondary care but not commonly prescribed by non-specialist doctors.  As the 174 
number of drug groups meeting these criteria exceeded 100, clinical and educational 175 
judgement was used to review the less commonly prescribed drugs from these lists, 176 
selecting those considered to be prescribed by generalists over those requiring more 177 
specialist expertise. In addition drugs from emergency guidelines that did not qualify 178 
by prescribing frequency but were considered to be clinically important were 179 
identified and room was made for them on the list by removing more specialist 180 
drugs. 181 
Comparison of methodology between 2006-9 and 2015 182 
Prescription cost analysis data was used to analyse items dispensed in the 183 
community in both 2006-9 and 2015 using broadly similar approaches. Minor 184 
changes in 2015 included a pre-planned decision to exclude intravenous fluids and 185 
vaccines from the analysis and to exclude combination products (e.g. analgesia, 186 
inhalers) from the final list where the constituent drugs were already included. 187 
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The main difference between studies was in the methods used to obtain the 188 
secondary care data. In 2006-9, a by-hand audit of paper drug charts of inpatients in 189 
two London hospitals was used to identify 7705 individual prescriptions. In 2015, a 190 
list of all (2.129 million) items prescribed that year in a single large teaching hospital 191 
was obtained from their electronic prescribing system. The 2015 secondary care data 192 
gives a much more comprehensive picture of secondary care prescribing, albeit from 193 
a single hospital with some distinct tertiary practice. 194 
  195 
Results 196 
The PCA 2015 dataset comprised 1.037 billion dispensed items, of which 24.775 197 
million items were ineligible for inclusion (figure 1). The Birmingham hospital data 198 
set comprised 2.129 million prescriptions, of which 360,000 prescriptions were 199 
ineligible for inclusion. The primary and secondary care analysis datasets therefore 200 
comprised 1.013 billion items dispensed and 1.779 million prescriptions respectively. 201 
Core drug list 202 
Eighty one drug groups that made up ≥0.1% items dispensed in primary care and 203 
prescriptions in secondary care comprised the majority of the list (table 1). Two 204 
drugs that met these criteria (nicorandil, 0.1% hospital prescriptions, 0.3% primary 205 
care items; hydroxychloroquine 0.1% hospital prescriptions, 0.1% primary care 206 
items) were considered more for specialist than generalist use and therefore not 207 
included in the final list. 208 
All 5 drug groups that made up ≥0.2% items dispensed in primary care alone were 209 
included in the core drug list (table 2). In addition, ‘drugs for breast cancer’, 210 
comprising 0.19% items dispensed) was included. 211 
Eleven drug groups made up ≥0.3% prescriptions in secondary care alone and 7 of 212 
these were included in the final list (table 3). The 4 drug groups excluded from the 213 
not included in the core final list because they were considered to require more 214 
specialist than generalist expertise were N-Methyl-D-aspartate receptor antagonists 215 
(e.g. ketamine), 1.9% prescriptions; immunosuppressants (e.g. tacrolimus, 216 
ciclosporin), 1.3% prescriptions; drugs for human immunodeficiency virus (HIV) 217 
infection (e.g. ritonavir), 1.1% prescriptions; and carbapenems (e.g. meropenem), 218 
0.5% prescriptions. 219 
Six drugs from emergency guidelines that did not qualify by prescribing frequency 220 
were considered clinically important and completed the list (table 4). 221 
Changes in core drug list from 2006-2009 to 2015 222 
There were 12 changes to the core list in 2015 from 2006-9 (table 5). Some of the 223 
drugs dropping out of the core drug list did so due to changes in qualification rules 224 
set in the prospectively defined analysis plan. Compound products were not included 225 
as distinct items if their constituent ingredients were already captured in the top 100 226 
list (compound beta 2 agonist/corticosteroid inhalers; opioids, compound 227 
preparations). Where different members of drug classes were used for more than 228 
one indication the drug class was included only once (anti-histamine anti-emetics 229 
and H1 receptor antagonists were separate in the old list and combined in the new 230 
list). Vaccines and antisera were excluded because, although they fall within the 231 
definition of medicinal products, we judged that they were educationally distinct. 232 
Electrolytes were split and analysed as their constituents (e.g. oral potassium, oral 233 
magnesium, intravenous electrolytes), which didn’t individually make the list based 234 
on prescribing frequency. 235 
 236 
Other drugs dropping out of the core list did so due to a fall in prescribing frequency 237 
relative to new entrants. These were anti-emetics, phenothiazines; dipyridamole; 238 
diuretics, potassium-sparing diuretics with other diuretics; laxatives, bulk forming, 239 
phenytoin and thiazolidinediones. Nicorandil was borderline for inclusion on the 240 
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basis of prescribing frequency, but was excluded from the final list to make room for 241 
emergency medicines as it was judged more specialist than generalist compared to 242 
other borderline drugs. 243 
All new entrants to the list qualified through an increase in relative prescribing 244 
frequency. For some drugs this represents a genuine increase in use e.g. direct oral 245 
anticoagulants, DPP-4 inhibitors, levetiracetam. For others, drug use may have 246 
remained constant but increased relative to some of those leaving the list (e.g. 247 
thiazolidinediones, phenytoin) where use has decreased. 248 
Drug groups that dropped out of the list included those used with decreasing 249 
frequency (e.g. thiazolidinediones, phenytoin, potassium-sparing diuretics) or 250 
excluded by new list criteria (e.g. compound products for which the constituent 251 
drugs were already part of the list, vaccines, combining entries of drugs used in more 252 
than one therapeutic area). Drugs entering the list were those where frequency of 253 
prescription or dispensing had increased relative to other drugs used in primary and 254 
secondary care settings. 255 
Comparison of core drugs list to the World Health Organisation list of essential 256 
medicines 257 
The World Health Organisation (WHO) compiles and updates a core list of minimum 258 
medicines required for a basic health-care system and a complementary list of 259 
essential medicines for priority diseases where some specialist facilities, care or 260 
training are needed for their use [12]. Together these lists contain around 438 261 
individual drugs. To determine the applicability of the core drug list to trainee 262 
prescribers working in healthcare systems outside England we compared our list to 263 
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the World Health Organisation list of essential medicines [12]. Seventy eight percent 264 
of our core drugs were on the WHO essential list and 4% were on the 265 
complementary list. Drugs not on the WHO list or on the complementary list only are 266 
shown in table 6. 267 
  268 
Discussion 269 
We have identified the drug groups most commonly prescribed in England in primary 270 
and secondary care settings in 2015. We have used this analysis to develop a ‘top 271 
100 drugs’ list to provide a starting point for trainee prescribers being introduced to 272 
pharmacology for the first time. This new list updates our previous analysis of 2006-9 273 
prescribing data [6]. Reassuringly, only 12% of drugs in the list have changed, 274 
indicating that learning based on this resource could have long term relevance for 275 
prescribing in practice. 276 
Some of the changes in the updated list reflect changes in qualification rules, such as 277 
removal of separate entries for compound preparations and drug groups used in 278 
more than one therapeutic area. Other changes however are likely to reflect genuine 279 
changes in prescribing guidelines and practice. For example, in 2010 the European 280 
Committee on Medicinal Products for Human Use recommended suspension of the 281 
marketing authorisation of rosiglitazone, a thiazolidinedione, due to emerging 282 
evidence of cardiovascular risk [13]. Another thiazolidinedione, troglitazone, had 283 
previously been withdrawn from the British market in 1997 due to hepatotoxicity 284 
[14]. Although pioglitazone, remains available for prescription and is still included in 285 
English guidelines produced by the National Institute for Health and Care Excellence 286 
(NICE) for the management of type 2 diabetes [15], concerns about the safety of this 287 
drug class and adoption of alternatives, including the dipeptidyl peptidase-4 288 
inhibitors (entering the list in 2015), likely account for the fall in thiazolidinedione 289 
prescribing. Another example is change in antiepileptic drug prescribing. Phenytoin, 290 
which was included in the 2006-9 list, was put on a ‘potential signals of serious risks’ 291 
list by the United States Food and Drug Administration (FDA) in 2008 and is no 292 
longer recommended as either first line or adjunctive therapy for the prevention of 293 
any seizure type by NICE [16]. Carbamazepine and sodium valproate (in both old and 294 
new lists), as well as lamotrigine and levetiracetam (entering the list in 2015), are 295 
preferred. Phenytoin remains on the World Health Organisation List of essential 296 
medicines [12] and is still listed in NICE guidelines as adjunctive treatment to 297 
benzodiazepines for status epilepticus. There is therefore a case to include it in the 298 
top 100 list as an emergency drug. As trials seek to replace its use even for status 299 
epilepticus with safer alternatives [17], we have made the judgement to leave it out 300 
of our list. Other educators and learners may wish to include it in theirs.  301 
We can only speculate on the reasons for changes in prescribing frequency. They 302 
may reflect shifts in prescribing practice, such as less frequent use of phenytoin in 303 
favour of better tolerated antiepileptic agents such as levetiracetam and 304 
lamotrigine. Other changes in the list may be due to increasing disease prevalence or 305 
diagnosis. For example increasing rates of diagnosis of dementia and prescription of 306 
anti-dementia drugs [1218] could be responsible for the entry of 307 
acetylcholinesterase inhibitors to the list. Differences in data collection between the 308 
two analyses may also have had an effect. In 2006-9, secondary care prescribing data 309 
was collected by hand and so only included approximately 7,500 prescriptions, 310 
whereas in 2015 use of electronic prescribing data allowed inclusion of nearly 1.8 311 
million secondary care prescriptions. 312 
Our list was developed using prescribing and dispensing data from England. To 313 
determine its relevance to an international audience we reviewed it against the 314 
WHO essential and complementary medicines lists [12]. Over three quarters of drugs 315 
on our list are considered essential for a basic healthcare system and are therefore 316 
likely to be used worldwide. We considered the WHO list in its entirety (438 drugs) 317 
to be overwhelming for a beginner prescriber and feel that our core list has an 318 
important place in helping novice prescribers to direct most of their initial attention 319 
to the most commonly prescribed drugs. 320 
A list of drugs to learn about perhaps seems an old fashioned concept in an era 321 
where healthcare education seeks to be patient-centred, integrated and problem-322 
based and curricula are moving to define and assess higher level competencies. 323 
Learning to prescribe is a complex process, well suited to a spiral curriculum where 324 
learners acquire understanding of the principles of clinical pharmacology, knowledge 325 
of drugs and therapeutics, and skills in prescribing in parallel, through multiple 326 
‘visits’ to the topic of increasing complexity [19]. A core drug list gives trainee 327 
prescribers a tool to focus their acquisition of knowledge around drugs that they will 328 
use in early clinical practice. It allows them to build their learning from knowledge of 329 
the pharmacology of individual drugs, through understanding how these drugs are 330 
used in the management of common diseases to prescribing them in simulated, then 331 
real, clinical scenarios. The principles and skills developed can then be applied to 332 
unfamiliar drugs encountered in practice. A core drug list can also help educators to 333 
design useful learning resources [7] and assessments that are relevant to practice. 334 
For example learners could be assessed on their knowledge of drugs on the core list, 335 
but on their skills in information gathering to support safe prescribing of an 336 
unfamiliar drug. 337 
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 338 
Limitations 339 
Our analysis has several limitations. The primary care data reflects English 340 
prescribing practice only, although we consider that it should be broadly 341 
representative of UK practice. With an appropriate overlay of local clinical–342 
educational judgement, it may have broader generalisability. Our finding that over 343 
three quarters of drugs on the core list were also on the WHO essential medicines 344 
list supports this. Secondary care data was obtained from a single hospital, and may 345 
therefore be affected by local prescribing patterns, population characteristics, and 346 
specialist services. However, it is reassuring that the large majority of items ion the 347 
list were prescribed frequently in both primary and secondary care, suggesting that 348 
most do not reflect specialist or centre-specific practice. Moreover, we applied 349 
clinical–educational judgment to exclude drugs considered to be mainly for specialist 350 
use and beyond the scope of a new prescriber.  351 
The method of analysis and definition of drug groupings also had potential to 352 
influence the results. The complex process of screening BNF sub-paragraphs, classes 353 
and individual drugs requires some subjective judgement. However, this was 354 
informed by considerable experience of both clinical practice and prescriber training, 355 
aiming to produce educationally useful, clinically relevant groups. These are fully 356 
described so that educators using the list may also apply their own judgment.  357 
Conclusion 358 
Formatted: Justified
Personal formularies are a valuable tools to improve prescribing skills, but can be 359 
difficult to develop without help for the trainee prescriber. We have produced a core 360 
drug list of the most commonly prescribed drug groups in the England to assist in 361 
this process. We consider that it should be generalisable to UK practice and – if 362 
supported by appropriate clinical–educational judgement – more widely. Updating 363 
this formulary has resulted in 12 changes from 2006-9, keeping the list up to date 364 
with contemporary prescribing practice. This core drug list is not intended to restrict 365 
the scope of teaching or to stifle students’ inquisitiveness. Rather, it should be 366 
considered as a ‘starter formulary’ to help novice prescribers to direct most of their 367 
early attention to the most commonly prescribed drugs. 368 
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Table 1. Drugs, classes and BNF groupings comprising ≥0.1% of both primary and 453 
hospital prescriptions 454 
 455 
Overall 
rank 
Drug, class or BNF 
grouping 
Most commonly prescribed 
example(s) 
Hosp. 
rank 
PCA 
rank 
Hosp. 
% 
PCA 
% 
1 Proton pump inhibitors omeprazole, lansoprazole 3 2 3.0% 5.5% 
2 Statins simvastatin, atorvastatin, pravastatin 9 1 2.3% 6.5% 
3 Paracetamol  1 11 6.2% 2.3% 
4 Beta-blockers bisoprolol, atenolol, propranolol 17 5 1.8% 3.6% 
5 Calcium and vitamin D  11 12 2.1% 2.1% 
6 Calcium-channel blockers amlodipine, felodipine, diltiazem, 
nifedipine, lercanidipine  
21 4 1.8% 3.7% 
7 H1 receptor antagonists cyclizine, cetirizine, loratadine, 
fexofenadine, chlorphenamine 
6 19 2.7% 1.6% 
8 Aspirin  18 8 1.8% 2.8% 
9 Opioids: weak/moderate tramadol, codeine, dihydrocodeine 5 21 2.8% 1.4% 
10 Opioids: strong morphine 2 27 5.2% 1.2% 
11 Beta2 agonists salbutamol, salmeterol 22 10 1.5% 2.3% 
12 Angiotensin-converting 
enzyme inhibitors 
ramipril, lisinopril, perindopril 30 3 1.1% 4.3% 
13 Diuretics, loop furosemide, bumetanide 12 22 2.1% 1.4% 
14 Vitamin K antagonists warfarin 6 28 2.5% 1.1% 
15 Vitamins folic acid, thiamine hydrochloride, 
vitamin B group 
16 20 1.8% 1.5% 
16 Non-steroidal anti-
inflammatory drugs 
naproxen, ibuprofen 28 13 1.1% 2.1% 
17 Penicillins, broad 
spectrum 
amoxicillin, co-amoxiclav 19 24 1.8% 1.4% 
18 Laxatives - osmotic macrogol, lactulose 13 33 2.1% 0.9% 
19 Anti-depressants, selective 
serotonin re-uptake 
inhibitors 
citalopram, sertraline, fluoxetine 42 6 0.7% 3.2% 
20 Corticosteroids, systemic prednisolone 10 38 2.1% 0.8% 
21 Laxatives, stimulant senna, docusate sodium 7 41 2.5% 0.7% 
22 Corticosteroids, inhaled beclometasone, fluticasone, 
budesonide 
39 14 0.8% 2.0% 
23 Thyroid hormones levothyroxine 50 7 0.6% 2.9% 
24 Benzodiazepines diazepam, temazepam, lorazepam 26 32 1.2% 1.0% 
25 Alpha-adrenoceptor 
blocking drugs 
doxazosin, tamsulosin 34 25 0.8% 1.3% 
26 MetforminBiguanides metformin 45 15 0.7% 1.9% 
27 Insulin  24 43 1.3% 0.7% 
28 Angiotensin-II receptor 
antagonists 
losartan, candesartan, irbesartan 54 16 0.5% 1.8% 
29 Corticosteroids, topical hydrocortisone 63 9 0.4% 2.4% 
30 Gabapentin and 
pregabalin 
 43 29 0.7% 1.0% 
31 Anti-depressants, tricyclic 
and related drugs 
amitriptyline 56 19 0.4% 1.6% 
32 Anti-platelet drugs clopidogrel 41 34 0.7% 0.9% 
33 Anti-fungal drugs clotrimazole, ketononazole 31 45 1.0% 0.6% 
34 Histamine (H2)-receptor 
antagonists 
ranitidine 25 51 1.3% 0.5% 
35 Diuretics, thiazide and 
thiazide-like 
Bendroflumethiazide, indapamide 65 18 0.3% 1.7% 
36 Emollients  58 31 0.4% 1.0% 
37 Nitrates isosorbide mononitrate, glyceryl 
trinitrate 
48 42 0.6% 0.7% 
38 Trimethoprim  35 55 0.8% 0.4% 
39 Iron ferrous fumarate, ferrous sulfate 51 40 0.6% 0.7% 
40 Bisphosphonates alendronic acid 57 36 0.4% 0.8% 
41 Penicillins, penicillinase-
resistant 
flucloxacillin 46 54 0.6% 0.4% 
42 Sulfonylureas gliclazide 67 35 0.3% 0.8% 
43 Macrolides clarithromycin 53 49 0.5% 0.5% 
44 Gout and hyperuricaemia allopurinol 60 48 0.4% 0.5% 
45 Alginates and antacids  59 50 0.4% 0.5% 
46 Anti-depressant drugs, 
other 
venlafaxine, mirtazapine 80 30 0.2% 1.0% 
47 Z drugs zopiclone 66 46 0.3% 0.6% 
48 Ocular lubricants (artificial 
tears) 
hypromellose 75 39 0.3% 0.8% 
49 Anti-emetics, dopamine 
(D2)-receptor antagonists 
metoclopramide, domperidone 27 88 1.2% 0.2% 
50 Anti-muscarinics, 
cardiovascular and 
gastrointestinal uses 
atropine, hyoscine butylbromide 52 64 0.1% 0.5% 
51 Anti-psychotics: 2nd quetiapine, olanzapine, risperidone 81 37 0.2% 0.8% 
generation 
52 Anti-muscarinics, 
bronchodilators 
tiotropium, ipratropium bromide 73 47 0.3% 0.6% 
53 DigoxinCardiac glycosides digoxin 61 61 0.4% 0.3% 
54 Methotrexate  44 79 0.7% 0.2% 
55 Anti-muscarinics, 
genitourinary uses 
solifenacin, tolterodine, oxybutynin 92 44 0.2% 0.6% 
56 Anti-proliferative 
immunosuppressants 
azathioprine 32 104 1.0% 0.1% 
57 Tetracyclines doxycycline 90 52 0.2% 0.4% 
58 Aldosterone antagonists spironolactone 76 66 0.3% 0.3% 
59 Metronidazole  64 81 0.4% 0.2% 
60 Dipeptidyl peptidase-4 
inhibitors 
sitagliptin, linagliptin 95 57 0.2% 0.4% 
61 Anti-motility drugs loperamide 68 84 0.3% 0.2% 
62 Quinine sulfate  97 56 0.2% 0.4% 
63 Dopaminergic drugs used 
in parkinsonism 
co-careldopa (carbidopa / levodopa)  99 58 0.2% 0.4% 
64 Lamotrigine  101 59 0.2% 0.4% 
65 Direct oral anticoagulants rivaroxaban, apixaban, dabigatran 94 69 0.2% 0.3% 
66 Anti-psychotics: 1st 
generation 
haloperidol  69 94 0.3% 0.1% 
67 Mucolytics carbocisteine 81 78 0.2% 0.2% 
68 Levetiracetam  74 90 0.3% 0.2% 
69 Prostaglandin analogues latanoprost 112 53 0.1% 0.4% 
70 Penicillin benzylpenicillin, 
phenoxymethylpenicillin 
93 75 0.2% 0.2% 
71 Valproate  107 63 0.1% 0.3% 
72 5α-reductase inhibitors finasteride 109 62 0.1% 0.3% 
73 Chloramphenicol   115 65 0.1% 0.3% 
74 Aminosalicylates mesalazine 103 77 0.1% 0.2% 
75 Nitrofurantoin  113 73 0.1% 0.2% 
76 Carbamazepine  117 72 0.1% 0.2% 
77 Antivirals aciclovir 84 105 0.2% 0.1% 
78 Cephalosporins ceftriaxone, cefalexin 85 106 0.2% 0.1% 
79 Local anaesthetics lidocaine 116 92 0.1% 0.1% 
80 Amiodarone  100 108 0.2% 0.1% 
81 Drugs used in substance nicotine, methadone 111 100 0.1% 0.1% 
dependence 
 456 
Abbreviations: BNF, British national formulary; PCA, prescription cost analysis; Hosp., 457 
hospital. 458 
For each drug the prescribing frequency in terms of rank and percentage of 459 
prescriptions are shown for both primary (PCA) and secondary (hosp.) care. The 460 
average rank in both healthcare settings was calculated and determined the overall 461 
rank. 462 
 463 
  464 
Table 2. Drugs, classes and BNF groupings comprising ≥0.2% prescriptions in 465 
primary care but <0.1% prescriptions in secondary care 466 
 467 
 Drug, class or BNF grouping Most commonly 
prescribed example(s) 
PCA rank PCA 
(%) 
1 Oestrogens and progestogens combined 
ethinylestradiol, 
desogestrel, estradiol 
27 1.2% 
2 Phosphodiesterase (type 5) 
inhibitors 
sildenafil 61 0.3% 
3 Acetylcholinesterase inhibitors donepezil 72 0.2% 
4 Serotonin (5HT1)-receptor agonists sumatriptan 75 0.2% 
5 Leukotriene receptor antagonists montelukast 79 0.2% 
6 Drugs for bBreast cancer tamoxifen 83 0.19% 
 468 
Abbreviations: BNF, British national formulary; PCA, prescription cost analysis 469 
  470 
Table 3. Drugs, classes and BNF groupings comprising ≥0.3% prescriptions in 471 
secondary care but <0.1% prescriptions in primary care 472 
 473 
 Drug, class or BNF grouping Most commonly 
prescribed example(s) 
Hosp. 
rank 
Hosp % 
1 Heparins enoxaparin, heparin 4 2.9% 
2 Serotonin (5HT3)-receptor 
antagonists 
ondansetron 8 2.4% 
3 Oxygen  21 1.7% 
4 Quinolones ciprofloxacin, 
moxifloxacin 
37 0.8% 
5 Penicillins, anti-pseudomonal piperacillin 
sodium/tazobactam 
sodium 
38 0.8% 
6 Vancomycin  48 0.6% 
7 Aminoglycosides gentamicin 72 0.3% 
 474 
Abbreviations: BNF, British national formulary; Hosp., hospital. 475 
 476 
  477 
Table 4. Drugs identified from emergency guidelines not qualifying for the core list 478 
by prescribing frequency but considered to be core learning for new prescribers 479 
 480 
1 Activated charcoal 
2 Adrenaline (epinephrine) 
3 Adenosine 
4 Acetylcysteine 
5 Fibrinolytics e.g. alteplase 
6 Naloxone 
 481 
Drugs from emergency guidelines are in alphabetical order 482 
 483 
  484 
Table 5. Changes in core drug list between 2006-9 and 2015 485 
 486 
Drugs dropping out of the core list New entrants to the list 
Anti-emetics, phenothiazines2 Acetylcholinesterase inhibitors 
Compound (beta-2 agonist corticosteroid) 
inhalers1 
Antiproliferative immunosuppressants 
Dipyridamole2 Antivirals 
Potassium, oral 
Electrolytes e.g. potassium, magnesium1 
Sex hormone antagonists for breast 
cancer 
Laxatives, bulk forming2 Chloramphenicol  
Nicorandil3 Dipeptidyl peptidase-4 inhibitors 
Opioids, compound preparations1 Lamotrigine 
Phenytoin2 Leukotriene receptor antagonists 
Diuretics, potassium-sparing 
Potassium sparing diuretics with other 
diuretics (e.g. co-amilofruse)2 
Levetiracetam 
Thiazolidinediones2 Direct oral anticoagulants 
Vaccines and antisera1 Serotonin (5HT1)-receptor agonists 
Anti-histamine anti-emetics combined with 
H1 receptor antagonists in the new list1 
Mucolytics 
 487 
1. Drugs dropping out of the list due to changes in qualification rules 488 
2. Drugs dropping out of the list due to reduction in relative prescribing or 489 
dispensing frequency 490 
3. Drug with more specialist use making way for drugs for more generalist use 491 
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Table 6. Drugs in the English top 100 starter formulary that are not in the World 492 
Health Organisation’s essential medicines list 493 
 494 
1 Alpha-adrenoceptor blocking drugs 
2 Gabapentin and pregabalin 
3 Emollients 
4 Alginates and antacids 
5 Anti-depressant drugs, other (venlafaxine, mirtazapine) 
6 Z drugs 
7 Ocular lubricants (artificial tears) 
8 Anti-muscarinics, genitourinary uses 
9 Dipeptidyl peptidase-4 inhibitors 
10 Direct oral anticoagulants 
11 Mucolytics e.g. carbocisteine 
12 Levetiracetam 
13 5α-reductase inhibitors 
14 Phosphodiesterase (type 5) inhibitors 
15 Acetylcholinesterase inhibitors 
16 Serotonin (5HT1)-receptor agonists 
17 Leukotriene receptor antagonists 
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18 Adenosine 
On the complementary list 
19 Anti-proliferative immunosuppressants e.g. azathioprine 
20 Amiodarone 
21 Drugs for breast cancer e.g. tamoxifen 
22 Fibrinolytics e.g. streptokinase 
 495 
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Figure legends 498 
 499 
Figure 1 500 
Flow diagram showing acquisition, exclusion and processing of prescribing data from 501 
primary and secondary care and emergency guidelines to produce the core drug list 502 
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